XML 165 R110.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Collaborative and Other Relationships (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN | $ 2,502.9 | $ 2,539.6 | $ 2,466.0 | $ 2,309.4 | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 9,817.9 | $ 9,188.5 | $ 8,203.4
Total revenues from anti-CD20 therapeutic programs | $ 318.2 | $ 317.6 | $ 349.2 | $ 329.5 | $ 333.9 | $ 337.2 | $ 337.5 | $ 330.6 | 1,314.5 | 1,339.2 | 1,195.4
U.S |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN |  |  |  |  |  |  |  |  | 7,050.4 | 6,545.8 | 5,566.7
Total revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 1,249.5 | 1,269.8 | 1,117.1
Roche Group - Genentech |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |
Total revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 1,314.5 | 1,339.2 | 1,195.4
Roche Group - Genentech | U.S |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses |  |  |  |  |  |  |  |  | $ 1,249.5 | 1,269.8 | 1,117.1
GAZYVA |  |  |  |  |  |  |  |  |  |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  | 39.00% |  |
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  |  |  |  |  | 37.50% |  |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  | 35.00% |  |
RITUXAN |  |  |  |  |  |  |  |  |  |  |
Co-promotion profit sharing formula |  |  |  |  |  |  |  |  |  |  |
Until GAZYVA First Non-CLL FDA Approval | 40.00% |  |  |  |  |  |  |  | 40.00% |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  | 39.00% |  |
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  |  |  |  |  | 37.50% |  |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  | 35.00% |  |
RITUXAN | Roche Group - Genentech | Outside the U.S |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN |  |  |  |  |  |  |  |  | $ 65.0 | $ 69.4 | $ 78.3

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option three. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenues from unconsolidated joint business. + References No definition available. + Details
Name: | biib_RevenuesFromUnconsolidatedJointBusinessAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada. + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprograms
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_GAZYVAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_RituxanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |